Evaluation of the Effects of PM101, a Cyclodextrin-Based Formulation of Intravenous Amiodarone, on Blood Pressure in Healthy Humans

American Journal of Cardiology

Volumn 104, Issue 8, 2009, Pages 1152-1157

  Cushing, Daniel J ^a   Adams, Michael P ^b   Cooper, Warren D ^a   Zhang, Bing ^b   Lipicky, Raymond J ^c   Kowey, Peter R ^a  

^a Prism Pharmaceuticals Inc   (United States)

^b Macrostat Inc ^*  (United States)

^c LANKENAU HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BENZYL ALCOHOL; BETA CYCLODEXTRIN SULFOBUTYL ETHER; GLUCOSE; PLACEBO; PM 101; POLYSORBATE 80; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DILUTION; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART RATE; HEMODYNAMICS; HOLTER MONITORING; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INFUSION RATE; INJECTION PAIN; INJECTION SITE COLDNESS; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LOADING DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASCULAR DISEASE; VOMITING;

ADOLESCENT; ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BETA-CYCLODEXTRINS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROGNOSIS; REFERENCE VALUES; YOUNG ADULT;

EID: 70349514998     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.010     Document Type: Article

References (15)

1. Mosher G., Johnson K.T., and Gayed A.A. Formulations containing amiodarone to polyvinylchloride infusion bags and administration sets. US Patent 6,869,939 (March 22, 2005)
2. Cushing D.J., Adams M.P., Cooper W.D., Kowey P.R., and Lipicky R.J. Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol 49 (2009) 407-415
3. Prism Pharmaceuticals, Inc. Nexterone (amiodarone HCI) injection [prescribing information] (2008), Prism Pharmaceuticals, Inc, King of Prussia, PA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/0223251b1.pdf Accessed July 15, 2009
4. Cushing D.J., Kowey P.R., Cooper W.D., Massey B.W., Gralinski M.R., and Lipicky R.J. PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. Eur J Pharmacol 607 (2009) 167-172
5. Abraxis Pharmaceutical Products. Amiodarone hydrochloride injection [prescribing information] (2008), Abraxis Pharmaceutical Products, Schaumburg, Illinois. http://www.apppharma.com/PIs/6-PI_Amiodarone_HCI_Inj_45887H.pdf Accessed July 14, 2009
6. Anastasiou-Nana M.I., Nanas J.N., Alexopoulos G., Karli J.N., Margari Z.J., Agapitos E., Patsi E.N., and Stamatelopoulos S.F. Amiodarone concentration in human myocardium after rapid intravenous administration. Cardiovasc Drugs Ther 13 (1999) 265-270
7. Sicart M., Besse P., Choussat A., and Bricaud H. Hemodynamic effects of intravenous amiodarone in humans. Arch Mal Coeur Vaiss 70 (1977) 219-227
8. Munoz A., Karila P., Gallay P., Zettelmeier F., Messner P., Mery M., and Grolleau R. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 9 (1988) 142-148
9. Somberg J.C., and Molnar J. The quest for an aqueous amiodarone. Am J Ther 10 (2003) 458-461
10. Somberg J.C., Cvetanovic I., Ranade V., and Molnar J. Comparative effects of rapid bolus administration of aqueous amiodarone versus 10-minute Cordarone i.v. infusion on mean arterial blood pressure in conscious dogs. Cardiovasc Drugs Ther 18 (2004) 345-351
11. Gough W.B., Zeiler R.H., Barreca P., and El-Sherif N. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J Cardiovasc Pharmacol 4 (1982) 375-380
12. Somberg J.C., Timar S., Bailin S.J., Lakatos F., Haffajee C.I., Tarjan J., Paladino W.P., Sarosi I., Kerin N.Z., Borbola J., Bridges D.E., and Molnar J. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol 93 (2004) 576-581
13. Kosinski E.J., Albin J.B., Young E., Lewis S.M., and Leland Jr. O.S. Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol 4 (1984) 565-570
14. Remme W.J., Kruyssen H.A., Look M.P., van Hoogenhuyze D.C., and Krauss X.H. Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. Am Heart J 122 (1991) 96-103
15. Cinelli P., Romano S., Castaldo G., de Scalzi M., Citi S., and de Leonardis V. Computerized M-mode echocardiography in the assessment of cardiovascular effects during intravenous administration of amiodarone. Methods Find Exp Clin Pharmacol 6 (1984) 27-32